[Thalidomide--a new prospective therapy in rheumatology and transplantation].
This review article discusses the thalidomide therapy of diseases such as systemic sclerosis, rheumatoid arthritis, Behçet syndrome, lupus erythematosus disseminatus and graft-versus-host disease. The main mechanism of action of thalidomide in these diseases is probably based on the suppression of tumor necrosis factor-alpha and the modulation of interleukins.
Pałgan
Krzysztof
K
Katedry i Kliniki Alergologii i Chorób Wewnetrznych, Akademii Medycznej im. L Rydygiera w Bydgoszczy.
Pałgan
Izabela
I
Dziedziczko
Andrzej
A
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001528:Behcet Syndrome / Q000188:drug therapy*; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007378:Interleukins / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D013792:Thalidomide / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects
D007166:Immunosuppressive Agents; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide